<DOC>
	<DOCNO>NCT00000327</DOCNO>
	<brief_summary>The purpose study compare clinical efficacy daily vs. 3-day ( MWF ) buprenorphine/naloxone combination tablet administration determine whether outcome improve use 3-day schedule dos ingest clinic vs. one take-home dos give intervening day .</brief_summary>
	<brief_title>Buprenorphine/Naloxone Treatment Opioid Dependence-Experiment I ( 2 ) - 2</brief_title>
	<detailed_description>Mon/Wed/Fri dose 8 mg buprenorphine/naloxone tablet safe effective daily dosing preferred patient daily dose . Multiple dos combination tablet ( e.g . 16mg , 24mg ) well tolerated patient . A 3 day schedule take-outs effective 3-day schedule medication ingest clinic</detailed_description>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Heroin Dependence</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<criteria>Individual must currently dependent meet FDA criterion narcotic maintenance treatment . Comorbid substance abuse dependence disorder may also present . Individuals must healthy despite drug dependency . Individuals evidence active Diagnostic Statistical Manual Mental Disorders ( DSMIV ) Axis I psychiatric disorder ( e.g. , psychosis , manicdepressive illness , organic psychiatric disorder ) , significant medical illness ( e.g . liver cardiovascular disease ) pregnant female subject exclude study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>62 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>drug dependence</keyword>
</DOC>